Between these 2 groups, there were no significant differences in other clinicopathologic factors that can affect PFS 29–31; tumor burden (%, P = 0.16), previous history of chemotherapy (P = 0.47), previous history of surgery (P = 0.23), extrahepatic metastases (P = 0.84), tumor type (P = 0.13), sex (P = 0.77), abnormal pre-SIRT total bilirubin (>1.3 mg/dL, P = 0.80), abnormal pre-SIRT serum albumin (<3.5 g/dL, P = 0.69), and poor performance status (ECOG grade >0, P = 0.84). This evidence concerns the gene ALB and neoplasm.